Research presented at the Intelligent Systems for Molecular Biology conference shows promise in uncovering more SNP-phenotype links in GWAS.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
In PLOS this week: cancer predisposition among Cowden/Cowden-like and Bannayan-Riley-Ruvalcaba syndrome patients, and more.
In PNAS this week: computational approach combining cancer survival models and machine learning, auxin herbicide resistance mutation, and more.
Working with Case Western Reserve University, the firm will sequence fecal samples from individuals diagnosed with autism and provide results for free to the research community.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
The assay analyzes a digital image of tumor tissue sample to identify ER-positive breast cancer patients who are candidates for adjuvant chemotherapy.
The method detects somatic copy number alterations in whole-exome datasets without requiring input from users and irrespective of sequencing platform.
The tests will use PGT's VeriTag technology in order to detect drug-resistant mutations at the .1 percent level.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.